ITeos Therapeutics (ITeos Therapeutics) Net Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is ITeos Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. ITeos Therapeutics's Net Income for the three months ended in Dec. 2023 was $-30.55 Mil. ITeos Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, ITeos Therapeutics's net margin for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for ITeos Therapeutics's Net Margin % or its related term are showing as below:

ITOS' s Net Margin % Range Over the Past 10 Years
Min: -894.35 Med: 36.11 Max: 62.22
Current: -894.35

ITOS's Net Margin % is ranked worse than
71.98% of 1028 companies
in the Biotechnology industry
Industry Median: -159.44 vs ITOS: -894.35

ITeos Therapeutics Net Margin % Historical Data

The historical data trend for ITeos Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ITeos Therapeutics Net Margin % Chart

ITeos Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

Get a 7-Day Free Trial

62.22

36.11

-894.34

ITeos Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %	Get a 7-Day Free Trial															37.94	-123.47	-	-	-

Competitive Comparison of ITeos Therapeutics's Net Margin %

For the Biotechnology subindustry, ITeos Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ITeos Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ITeos Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where ITeos Therapeutics's Net Margin % falls into.

ITeos Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

ITeos Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-112.642	/	12.595
	=	-894.34 %

ITeos Therapeutics's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-30.551	/	0
	=	%

ITeos Therapeutics (NAS:ITOS) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

ITeos Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of ITeos Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ITeos Therapeutics (ITeos Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ITeos Therapeutics Inc (NAS:ITOS) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

321 Arsenal Street, Watertown, MA, USA, 02472

Website

https://www.iteostherapeutics.com

ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.

Executives

Matthew Gall	officer: Chief Financial Officer	C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Aaron I. Davis	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Joseph Lewis	other: See remarks	PO BOX N7776, LYFORD BAHAMAS
Boxer Asset Management Inc.	other: See remarks	CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Boxer Capital, Llc	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
David Hallal	director	C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Michel Detheux	director, officer: Chief Executive Officer	C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Yvonne Mcgrath	officer: VP, Research and Development	C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Joanne Jenkins Lager	officer: Chief Medical Officer	C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Ubs Oncology Impact Fund L.p.	other: X*	450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2014, L.p.	10 percent owner	C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2018, L.p.	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142
Detlev Biniszkiewicz	director	C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Tony W Ho	director	CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Robert Iannone	director	300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950